Oxford BioMedica

Oxford BioMedica is a pioneer of gene and cell therapy, with a leading industry position in lentiviral vector and cell therapy research, development and manufacture. Gene therapy is the treatment of disease by delivering therapeutic DNA into a patient’s cells. This can be either in vivo or ex vivo, the latter encompassing the field of cell therapy whereby genetically modified cells are put back into the body. Their pipeline of seven gene and cell therapy therapy products addresses diseases for which there is currently no treatment or that are inadequately treated today, including ocular and central nervous system disorders. Their product candidates have the potential to transform treatment landscapes. Their strategy is to develop their product candidates to their next value inflection points whilst continuing to build OXB Solutions into a valuable revenue-generating manufacturing and development services business.

Oxford BioMedica headquartered in Europe, operates in the Biotechnology, Therapeutics, Genetics sector. The company focuses on Biotechnology and has secured $9.4B in funding across 60 round(s). With a team of 501-1000 employees, Oxford BioMedica is actively contributing to advancements in Biotechnology. Their latest funding round, Post-IPO Equity - Oxford BioMedica, raised $69.8M. Discover more about their projects, partnerships, and impact on our platform.